Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.37 |
| ▸ | ITGAV | P06756 | 4/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | SI | P14410 | 4/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 4/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL6696461 | 0.98 | FFAR1 (0.37) | FFAR1ITGB3ITGAVITGA2BMGAM | |
| SCHEMBL6696463 | 0.92 | ITGB3 (0.36) | FFAR1ITGB3ITGAVITGA2BMGAM | |
| Trifluoroacetic Acid SCHEMBL6169546 | 0.92 | ITGB3 (0.35) | FFAR1ITGB3ITGAVITGA2BMGAM | |
| Trifluoroacetic Acid SCHEMBL6698561 | 0.91 | ITGB3 (0.37) | FFAR1ITGB3ITGAVMGAMGAA | |
| Trifluoroacetic Acid SCHEMBL6163731 | 0.91 | ITGB3 (0.40) | ITGB3ITGAVMGAMGAASI | |
| SCHEMBL6697813 | 0.91 | HAT1 (0.39) | FFAR1ITGB3ITGAVMGAMGAA | |
| SCHEMBL6162318 | 0.91 | MGAM (0.37) | ITGB3ITGAVMGAMGAASI | |
| Trifluoroacetic Acid SCHEMBL6701591 | 0.91 | MGAM (0.41) | ITGB3ITGAVITGA2BMGAMGAA | |
| Trifluoroacetic Acid SCHEMBL6692554 | 0.91 | MGAM (0.37) | ITGB3ITGAVMGAMGAASI | |
| Trifluoroacetic Acid SCHEMBL6701434 | 0.91 | MGAM (0.41) | ITGB3ITGAVITGA2BMGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138284-A1 | Indol-3-yl derivatives | WIESNER MATTHIAS | 2004-07-15 | — | — | US | disclosed |
| US-6743810-B2 | INTEGRIN INHIBITORS; TUMORS, OSTEOPOROSIS, OSTEOLYTIC DISEASES, SUPPRESSING ANGIOGENESIS, ANTITHROMBOTIC | MERCK PATENT GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | MERCK PATENT GMBH (DE) | 2003-03-06 | — | — | US | disclosed |
| EP-1254133-A2 | INDOL-3-YL DERIVATIVES | MERCK PATENT GmbH (DE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058893-A2 | INDOL-3-YL DERIVATIVES AND THEIR USE AS INTEGRIN INHIBITORS | MERCK PATENT GMBH (DE) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045728-A1 | Liberating 3-substituted indole compound from one of its functional derivatives by treatment with a solvolyzing or hydrogenating agent, amidation, saponification, alkylation or acylation, or salt formation | IGF1R, IDO1, ITGB3 | FFAR1 145/4885ITGB3 3/4885ITGAV 67/4885 |
| US-20040138284-A1 | Indol-3-yl derivatives | ITGB3, ITGB1, IGF1R | FFAR1 605/4885ITGB3 1/4885ITGAV 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.